---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-211130"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2024-08-30T23:59:59+00:00"
generated_at: "2026-05-31T06:46:52.109071+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics adopts amended indemnification agreements for directors and officers

## Summary
- Board approved amended form of indemnification agreement effective August 26, 2024.
- Revised change-of-control definition and added coverage of separate counsel expenses in change of control.
- Advancement of defense expenses clarified to be irrespective of insurance coverage.
- Includes express presumption of good faith in favor of Indemnitee (burden on challenger).
- Indemnitee may seek specific performance without showing irreparable harm.

## SEC filing metadata
- accession: 0001193125-24-211130
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2024-08-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312524211130/0001193125-24-211130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312524211130/d703760d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-211130
- JSON: https://secwatch.observer/filing/0001193125-24-211130.json
- Plain text: https://secwatch.observer/filing/0001193125-24-211130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.